These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
News & Analysis: Verastem
Verastem's new oncology drug isn't setting the world on fire.
VSTM earnings call for the period ending December 31, 2018.
Investors have been worried about a difficult new drug launch.
Convertible notes issued by the biotech will dilute investors.
The sell-off follows news of Verastem's first regulatory approval in oncology.
Hint: It has nothing to do with yesterday's earnings release.
Investors are piling into the small-cap drugmaker following a positive conference presentation.
Shares of Galectin Therapeutics and Verastem should both head higher in the coming week. Here's why.
A rate secondary offering with no discount gives investors the confidence to hit the buy button.